HCC70

The HCC70 cell line is derived from a triple-negative breast cancer (TNBC), a subtype that lacks expression of estrogen, progesterone, and HER2 receptors, making it difficult to treat due to limited targeted therapies. HCC70 cells are notable for their basal-like 1 (BL1) classification within TNBC subtypes, which impacts their response to chemotherapy and treatment strategies. Importantly, HCC70 cells express the G-protein-coupled estrogen receptor GPR30 at significant levels. GPR30 has been associated with rapid signaling responses to estrogens like 17β-estradiol, influencing cell proliferation and other oncogenic pathways. A key genetic characteristic of HCC70 is the presence of a TP53 mutation, specifically the R248Q variant. This mutation is associated with gain-of-function (GOF) phenotypes that contribute to cancer cell survival and aggressive behavior. In studies, R248Q mutation in HCC70 cells has been linked to enhanced cell deformability and altered PARP1 localization, implying potential sensitivity to PARP inhibitors. Research into drug responses in HCC70 and similar TNBC cell lines has highlighted the efficacy of proteasome inhibitors and platinum-based therapies. These treatments have shown promise, with drugs like bortezomib demonstrating cytotoxic effects. The interplay between chemotherapeutic resistance and specific receptor signaling, such as that mediated by GPR30, underscores the complexity of targeting TNBC subtypes like those modeled by HCC70. Breast cancer cell lines, Mammary gland, Breast ductal carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1